Talphera, Inc. Common Stock (TLPH) is a publicly traded Healthcare sector company. As of November 12, 2026, TLPH trades at $1.12 with a market cap of $54.50M and a P/E ratio of -3.18. TLPH moved -1.90% today. Year to date, TLPH is -16.02%; over the trailing twelve months it is -19.92%. Its 52-week range spans $0.38 to $1.57. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces TLPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Talphera Q3 loss beats estimates; NEPHRO enrollment and sales outlook advance: Talphera’s third-quarter net loss was $4.02 million, below the $4.35 million analyst estimate, and its operating loss of $4.14 million was below the $4.22 million estimate. The company is seeking FDA feedback on closing NEPHRO CRRT enrollment by Dec. 31, 2026, and estimates peak nafamostat sales in CRRT could exceed $200 million.
| Metric | Value |
|---|---|
| Price | $1.12 |
| Market Cap | $54.50M |
| P/E Ratio | -3.18 |
| EPS | $-0.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $1.57 |
| 52-Week Low | $0.38 |
| Volume | 76.01K |
| Avg Volume | 0 |
| Revenue (TTM) | $28.00K |
| Net Income | $-14.29M |
| Gross Margin | 0.00% |
2 analysts cover TLPH: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.